- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Type 2 diabetes

Type 2 diabetes is characterised by high blood glucose levels. This leads to serious health complications. Type 2 diabetes is strongly associated with obesity and ageing. In Australia 1.3 million people have type 2 diabetes, and its incidence in increasing. Our researchers are revealing how type 2 diabetes develops, and advancing new strategies to treat this condition.
Our type 2 diabetes research
Our type 2 diabetes research includes laboratory and clinical studies aimed at:
- Revealing how tissues become resistant to insulin and developing new strategies to reverse this.
- Defining the role of inflammation in type 2 diabetes, and investigating ways to reduce inflammation.
- Understanding how obesity contributes to type 2 diabetes.
- Develop novel insulin analogues that will make life easier for patients with type 2 diabetes.
What is type 2 diabetes?
High blood glucose levels occur in diabetes because the body does not respond properly to the hormone insulin, which controls glucose levels.
In type 2 diabetes, insulin is less effective in controlling blood glucose levels. This is because the key targets of insulin, liver and muscle cells, are less sensitive to its effects. This condition is termed ‘insulin resistance’.
Insulin resistance may be triggered by chronic inflammation. This is caused by immune cells within fat tissue releasing substances that inflame neighbouring tissues. The fatter a person becomes, the more inflammation their fat tissue generates.
Insulin resistance leads to high levels of glucose in the blood. This can reinforce insulin resistance, potentially by exacerbating inflammation. At the same time, high levels of glucose in the blood trigger more insulin release from the pancreas. This triggers inflammation within the pancreas, which kills the insulin-secreting beta cells. This leads to less insulin being produced, worsening the blood glucose levels and increasing inflammation.
Type 2 diabetes in Australia
Around 1.3 million Australians have been diagnosed with type 2 diabetes. It is estimated that another 500,000 Australians have the condition but have not been diagnosed, putting them at increased risk of complications. Complications of type 2 diabetes are a significant health burden for Australia.
Type 2 diabetes risk factors
A person’s risk of developing type 2 diabetes depends on their age and their genetic makeup, but also on ‘lifestyle’ factors.
Certain inherited, genetic factors increase a person’s chances of developing type 2 diabetes. This explains why relatives of someone with type 2 diabetes are more likely to also have this condition. It also explains why type 2 diabetes rates are higher in people from certain racial and ethnic groups. Aboriginal Australians have a high risk of developing type 2 diabetes.
A person’s chances of developing type 2 diabetes are increased if they:
- Are older: type 2 diabetes risk increases with age
- Are overweight or obese
- Have high blood pressure
- Have previously had gestational diabetes
- Are female
Reducing body weight and increasing physical fitness can reduce a person’s chances of developing type 2 diabetes.
How is type 2 diabetes treated?
The severity of type 2 diabetes can differ between people. Some people show insulin resistance but normal levels of insulin production; in other people, the condition is predominantly associated with reduced insulin production. These factors can also change with time.
The severity and characteristics of a person’s type 2 diabetes influences how they are treated. Blood glucose levels can often be controlled by regular exercise and eating a healthy diet, which does not raise blood sugar rapidly.
Our researchers are trialing whether weight loss can be used as a treatment for type 2 diabetes.
Some people with type 2 diabetes also require medications that:
- Reduce blood sugar levels.
- Improve how cells respond to insulin.
- Stimulate insulin production by the pancreas.
When insufficient insulin is produced, a person with type 2 diabetes needs to start taking additional insulin. This is given by injections or through a pump.
In the long term, people with type 2 diabetes may need additional treatments for complications of their condition. Common complications of type 2 diabetes include:
- Kidney disease (diabetic nephropathy)
- Eye disease and blindness (diabetic retinopathy)
- Nerve damage (diabetic neuropathy)
- Damage to blood vessels, which together with nerve damage can lead to serious problems in the hands and feet
- Heart disease and stroke.
For more information, and support for people with type 2 diabetes please visit Diabetes Australia.
Researchers:
Super Content:
Dr John Wentworth discusses clinical trial of gastric banding
How inflammatory cells in fat contribute to type 2 diabetes
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.